Patents by Inventor Philippe Mondon
Philippe Mondon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9737476Abstract: The present invention proposes an extract of Albizia Julibrissin for the cosmetic treatment of skin glycation. The extract is preferably obtained from flowers and/or seeds. Application to cosmetic formulations for treating cutaneous fatigue, in particular for improving the radiance of skin and eye contour (under eye bags and dark circles) and for treating the loss of skin suppleness. A preferred composition, particularly adapted for eye contour, comprises the Albizia Julibrissin extract combined with Darutoside that can be extracted from Siegesbeckia Orientalis.Type: GrantFiled: September 27, 2012Date of Patent: August 22, 2017Assignee: SedermaInventors: Arnaud Fournial, Claire-Marie Grizaud, Philippe Mondon
-
Publication number: 20170157014Abstract: The peptides have the general following formula: X-Pro*-Pro*-Xaa-Y in which: —Xaa is selected from Leucine (Leu, L), Arginine (Arg, R), Lysine (Lys, K), Alanine (Ala, A), Serine (Ser, S), and Aspartic acid (Asp, D); —At the N terminal end of the peptide, X is selected from H, —CO—R1 and —SO2—R1; —At the C terminal end of the peptide, Y is selected from OH, OR1, NH2, NHR1 and NR1R2; —R1 and R2 are, independently from each other, selected from an alkyle, aryle, aralkyle, alkylaryl, alkoxy and aryloxy group, that can be linear, branched, cyclic, poly-cyclic, non-saturated, hydroxylated, carbonylated, phosphorylated and/or sulfured, and which skeletum can comprise an heteroatom, in particular an O, S and/or N atom; —Pro* correspond to a Proline, an analogue or derivative thereof; —if X is H then Y is selected from OR1, NH2, NHR1 and NR1R2, and if Y is OH then X is —CO— or —SO2—R1; and the peptide hypoxanthine-Pro-Pro-Arg being excluded.Type: ApplicationFiled: May 21, 2015Publication date: June 8, 2017Applicant: SEDERMAInventors: OLIVIER PESCHARD, ANNE DOUCET, RICHARD LEROUX, PHILIPPE MONDON
-
Publication number: 20170071844Abstract: The invention is directed to the use of at least one peptide of formula: X-(Xaa1)n-Pro*-(Xaa2)m-Y (I) With: —n=0, 1 or 2; -m=0 or 1 and if m=0 then n?0-Xaa1 is: -An hydrophobic aminoacid selected from Alanine (Ala, A), Valine (Val, V), Methionine (Met, M), Leucine (Leu, L), Isoleucine (Ile, I), Phenylalanine (Phe, F), Proline (Pro, P) and analogues and derivatives thereof; —A polar aminoacid selected from Serine (Ser, S), Threonine (Thr, T), Tyrosine (Tyr, Y), Asparagine (Asn, N), Glutamine (Gln, Q) and analogues and derivatives thereof; —or Glycine (Gly, G); When n=2 the two aminoacids Xaa1 can be the same or different; -Xaa2 is: —An hydrophobic aminoacid selected from Alanine (Ala, A), Valine (Val, V), Methionine (Met, M), Leucine (Leu, L), Isoleucine (Ile, I), Phenylalanine (Phe, F), Proline (Pro, P) and analogues and derivatives thereof; —A basic aminoacid selected from Arginine (Arg, R), Lysine (Lys, K) and Histidine (His, H) and analogues and derivatives thereof; —Glycine (Gly, G) or Serine (Ser, S); —AType: ApplicationFiled: November 28, 2016Publication date: March 16, 2017Applicant: SedermaInventors: Olivier Peschard, Philippe Mondon
-
Patent number: 9534015Abstract: The invention is directed to the use of at least one peptide of formula: X-(Xaa1)n-Pro*-(Xaa2)m-Y (I) With: ?n=0, or 2; ?m=0 or 1 and if m=0 then n?0?Xaa is: —An hydrophobic aminoacid; —A polar aminoacid; or —Glycine (Gly, G); When n=2 the two aminoacids Xaa1 can be the same or different; —Xaa2 is: —An hydrophobic amino acid; —A basic aminoacid; —Glycine (Gly, G) or Serine (Ser, S); —At the N terminal end of the peptide, X is selected from H, —CO—R1 and —SO2—R1; —At the C terminal end of the peptide, Y is selected from OH, OR1, NH2, NHR1 or NR1R2, —R1 and R2 being independently from each other, selected from an alkyle, aryle, aralkyle, alkylaryl, alkoxy and aryloxy group; —Pro* Excluding the peptides where X=H and Y=OH, for a non therapeutical cosmetic pro-pigmenting treatment of skin.Type: GrantFiled: November 25, 2013Date of Patent: January 3, 2017Assignee: SedermaInventors: Olivier Peschard, Philippe Mondon
-
Patent number: 9346883Abstract: The invention relates to antibodies against HER3 and their use in the treatment of cancer.Type: GrantFiled: May 11, 2012Date of Patent: May 24, 2016Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Gamamabs Pharma SAInventors: Abdelhakim Kharrat, Olivier Dubreuil, Yassamine Lazrek, Philippe Mondon, Khalil Bouayadi, Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege A. Gaborit
-
Publication number: 20150274776Abstract: The invention is directed to the use of at least one peptide of formula: X-(Xaa1)n-Pro*-(Xaa2)m-Y (I) With: —n=0, or 2; —m=0 or land if m=0 then n?0 —Xaa is: —An hydrophobic aminoacid selected from Alanine (Ala, A), Valine (Val, V), Methionine (Met, M), Leucine (Leu, L), Isoleucine (Ile, I), Phenylalanine (Phe, F), Proline (Pro, P) and analogues and derivatives thereof; —A polar aminoacid selected from Serine (Ser, S), Threonine (Thr, T), Tyrosine (Tyr, Y), Asparagine (Asn, N), Glutamine (Gln, Q) and analogues and derivatives thereof; or —Glycine (Gly, G); When n=2 the two aminoacids Xaa1 can be the same or different; —Xaa2 is: —An hydrophobic aminoacid selected from Alanine (Ala, A), Valine (Val, V), Methionine (Met, M), Leucine (Leu, L), Isoleucine (Ile, I), Phenylalanine (Phe, F), Proline (Pro, P) and analogues and derivatives thereof; —A basic aminoacid selected from Arginine (Arg, R), Lysine (Lys, K) and Histidine (His, H) and analogues and derivatives thereof; —Glycine (Gly, G) or Serine (Ser, S); —At tType: ApplicationFiled: November 25, 2013Publication date: October 1, 2015Applicant: SEDERMAInventors: Olivier Peschard, Philippe Mondon
-
Patent number: 9126060Abstract: Geranylgeranyl-2-propanol compound (GGP) having the following formula I: is proposed for use according to the present invention as a cosmetic active compound for the prevention and treatment of aging of skin and its appendages. The GGP has a protective action against oxidative stress and free radical, on telomeres and on mitochondria and its activity. In particular, GGP can be used for the treatment of wrinkles, fine lines and visible discontinuities of skin, for the treatment pigmentation disorders.Type: GrantFiled: April 7, 2011Date of Patent: September 8, 2015Assignee: SEDERMAInventors: Arnaud Fournial, Philippe Mondon, Olivier Peschard
-
Publication number: 20150196475Abstract: The present invention relates to the field of cosmetic and dermopharmaceutical compositions. It concerns oligomer compounds of D-glucuronic acid or D-glucuronate with a ? (1-4) sequence (or oligoglucuronans) containing a degree of acetylation specifically between 8.7±0.5 and 9.2±0.5% by weight of O—CO—CH3 group compared to the weight of glucuronic acid and with a degree of polymerisation (DP) of 18-19±2. The oligomer compounds according to the present invention are intended to stimulate the elasticity of the dermis and epidermis although they also act to increase dermo-epidermal cohesion in order to combat skin ageing, lines, wrinkles, visible and/or tactile skin discontinuities, loss of firmness, elasticity and tone and to combat skin tissue deformability. The invention also concerns a cosmetic composition containing at least one compound as recited according to the present invention.Type: ApplicationFiled: March 23, 2015Publication date: July 16, 2015Inventors: Arnaud Fournial, Claire-Marie Grizaud, Caroline Le Moigne, Philippe Mondon
-
Patent number: 9050477Abstract: The present invention related to cosmetic compositions comprising oridonin and new cosmetic uses. Oridonin is used for fighting the signs of cutaneous aging and for slimming. A composition comprising a combination of oridonin and darutigenol or a derivative thereof, in particular darutoside, is disclosed together with the cosmetic use of such composition.Type: GrantFiled: April 15, 2010Date of Patent: June 9, 2015Assignee: SEDERMAInventors: Arnaud Fournial, Philippe Mondon
-
Publication number: 20150017269Abstract: The present invention proposes an extract of Albizia Julibrissin for the cosmetic treatment of skin glycation. The extract is preferably obtained from flowers and/or seeds. Application to cosmetic formulations for treating cutaneous fatigue, in particular for improving the radiance of skin and eye contour (under eye bags and dark circles) and for treating the loss of skin suppleness. A preferred composition, particularly adapted for eye contour, comprises the Albizia Julibrissin extract combined with Darutoside that can be extracted from Siegesbeckia Orientalis.Type: ApplicationFiled: September 27, 2012Publication date: January 15, 2015Applicant: SEDERMAInventors: Arnaud Fournial, Claire-Marie Grizaud, Philippe Mondon
-
Publication number: 20140378663Abstract: A method for producing a variant of a parent polypeptide including a Fc region, which variant exhibits reduced binding to the protein C1q and to at least one receptor Fcg? R as compared to the parent polypeptide.Type: ApplicationFiled: June 25, 2012Publication date: December 25, 2014Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DE BIOTECHNOLOGIESInventors: Alexandre Fontayne, Sylvie Jorieux, Celine Monnet-Mars, Philippe Mondon, Abdelhakim Kharrat, Khalil Bouayadi
-
Patent number: 8741357Abstract: The invention provides a cosmetic or dermopharmaceutic composition containing an Euglena extract, its use to activate the cellular metabolism and in particular to protect and/or improve the state of the skin and to reduce the signs of ageing in particular and/or cutaneous fatigue.Type: GrantFiled: January 13, 2006Date of Patent: June 3, 2014Assignee: Sederma SASInventors: Karl Lintner, Claire Mas Chamberlin, Louis François Lamy, Philippe Mondon
-
Patent number: 8742074Abstract: A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.Type: GrantFiled: March 19, 2010Date of Patent: June 3, 2014Assignee: Laboratoire Francais du Fractionnement et des BiotechnologiesInventors: Christian Behrens, Sylvie Jorieux, Abdelhakim Kharrat, Khalil Bouayadi, Philippe Mondon, Celine Monnet-Mars
-
Publication number: 20140141019Abstract: The invention relates to antibodies against HER3 and their use in the treatment of cancer.Type: ApplicationFiled: May 11, 2012Publication date: May 22, 2014Applicant: INSERM (INSTITUT NATIONALDE LA SENTE ET DE LA RECHERCHE MEDICALE)Inventors: Abdelhakim Kharrat, Olivier Dubreuil, Yassamine Lazrek, Philippe Mondon, Khalil Bouayadi, Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege A. Gaborit
-
Patent number: 8697656Abstract: The present invention concerns a peptide of following formula I: R being a side chain having at least one heteroatom selected from sulfur, nitrogen and oxygen in a carbonyl form (C?O); R1 being either H or a lipophilic chain; R2 being either OH or a lipophilic chain. More particularly the present invention concerns a cosmetic composition comprising a peptide as recited above and a physiologically acceptable medium. Results on the activity of the compounds are obtained and on the general state of the skin and its appendages, in particular via the stimulation of extracellular matrix components.Type: GrantFiled: January 15, 2010Date of Patent: April 15, 2014Assignee: SEDERMAInventors: Arnaud Fournial, Philippe Mondon, Olivier Peschard
-
Patent number: 8603498Abstract: The compound according to the invention has the following developed formula IX: wherein: X=PO(OH)2; SO2(OH); PO(OH)(Xaa)m or SO2(Xaa)m; A=H; OH; NH2 or akyl (1-6C); n=1 to 4; Y=—CO—OR2; —CO—NR3R4; —O—CO—R2; —C?CR2; R2=an alkyl, aryl, aralkyl, acyl, sulfonyl, sugar or alkoxy chain of 1 to 24 carbon atoms, linear, branched or cyclic, with or without substitutions, saturated or not, hydroxylated or not, sulfurated or not; R5=OH, O-alk (1-6C), (Xaa)m, NH2 or NH-alkyl(1-6C); Xaa=peptide of m aminoacids Xaa with m from 1 to 10; The compound is preferably phosphated, obtained from malic acid and having the following developed formula: A cosmetic composition comprising the compound of the present invention can improve the general condition of the skin, for example hydration, lightening and mechanical properties.Type: GrantFiled: January 17, 2011Date of Patent: December 10, 2013Assignee: Sederma, S.A.S.Inventors: Arnaud Fournial, Philippe Mondon, Olivier Peschard
-
Publication number: 20130309332Abstract: According to the present invention the extract of plant origin of the Globularia genus is used for a non-therapeutic cosmetic treatment of the skin and/or appendages. Preferably the species is Globularia cordifolia and the extract is obtained by in vitro plant culture. The extract can be used in particular for preventing and/or treating skin ageing by stimulating the 10 reactions of detoxification and cellular regeneration through a hormetic type response, for improving the transparency and radiance of complexion, for preventing or treating sensitive and reactive skins, for preventing or treating rednesses, for preventing protein glycation, for increasing and/or maintaining the number of dermal stem cells, for increasing and/or maintaining the dermal macromolecules, in particular collagen and elastin, for increasing the volume of the dermis, for 15 preventing and/or treating fines lines and wrinkles, for firming skin, for preventing hair loss and/or stimulating hair regrowth.Type: ApplicationFiled: January 30, 2012Publication date: November 21, 2013Applicant: SEDERMA, S.A.S.Inventors: Arnaud Fournial, Claire-Marie Grizaud, Philippe Mondon, Caroline Le Moigne
-
Patent number: 8404648Abstract: The invention concerns polypeptides of the general formula (I): A-(Xaa)n-Lys-X-Lys-B wherein: i) A is —NH2, NH3+, or NH-D (D is an acyl group being biotin or an alkyl chain (C2-C22)), H) B is H, O?OR1 or NR2R3 and R1, R2 and R3 independently either: H or an alkyl chain (C1-C24), iii) (Xaa)n is an amino acid chain including any amino acid natural or not, excluding arginine and lysine, iv) “n” is between 0-3, and v) X is either a chain of two any amino acids (Xaa1Xaa2) which may be the same or different, excluding arginine, lysine and excluding Xaa1Xaa2=Thr-Thr, Gly-His and Glu-His, or X is a spacer selected among beta-alanyl, 5-amino-valeroyl, 4-amino-cyclohexanoyl, 4-amino-butyroyl, 6-amino-caproyl and derivatives thereof. More particularly, the invention concerns polypeptides of formula (I) wherein “n” is 0 and with the formula: A-Lys-X-Lys-B; A, X and B being defined herein. Compositions containing at least one of said polypeptides and their use.Type: GrantFiled: February 16, 2006Date of Patent: March 26, 2013Assignee: SedermaInventors: Karl Lintner, Olivier Peschard, Philippe Mondon, Claire Mas Chamberlin
-
Publication number: 20130058878Abstract: Geranylgeranyl-2-propanol compound (GGP) having the following formula (I) is proposed for use according to the present invention as a cosmetic active compound for the prevention and treatment of aging of skin and its appendages. The GGP has a protective action against oxidative stress and free radical, on telomeres and on mitochondria and its activity. In particular, GGP can be used for the treatment of wrinkles, fine lines and visible discontinuities of skin, for the treatment pigmentation disorders.Type: ApplicationFiled: April 7, 2011Publication date: March 7, 2013Applicant: SEDERMAInventors: Arnaud Fournial, Philippe Mondon, Olivier Peschard
-
Patent number: RE45992Abstract: A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.Type: GrantFiled: July 23, 2014Date of Patent: May 3, 2016Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Christian Behrens, Sylvie Jorieux, Abdelhakim Kharrat, Khalil Bouayadi, Philippe Mondon, Celine Monnet-Mars